Skip to main content
. Author manuscript; available in PMC: 2022 Apr 12.
Published in final edited form as: Cancer Cell. 2021 Apr 12;39(4):566–579.e7. doi: 10.1016/j.ccell.2021.02.014

Figure 3: Trial design and efficacy of topotecan and M6620 in relapsed SCLC.

Figure 3:

A) Study schema. B) Tumor responses to the combination of M6620 and topotecan in SCLC patients based on maximum change in tumor dimensions from baseline. Each bar represents a patient’s tumor response. C) Efficacy of the combination based on duration of response, and D) change in target lesion size from baseline. E) CT abdomen showing tumor regression in a patient (patient # 42) with platinum-resistant SCLC and liver metastasis (red arrows). F) CT chest showing tumor regression in a patient (patient #50) with platinum-resistant SCLC and hilar lymph node metastases (red arrows). G) Differences of EpCAM+ CTCs in patients with disease control (PR + SD ≥4 months, red triangles) vs. those without (blue circles). The number of samples (non-disease control vs. disease control): 10 vs. 13, 8 vs. 14, 5 vs. 8 pre-treatment, 3 weeks after treatment, and at disease progression, respectively. Median and interquartile ranges are shown. Statistical differences are evaluated by Mann-Whitney U test. H) Differences of CD117+ EpCAM+ CTCs in patients with disease control (PR + SD ≥4 months, red triangles) vs. those without (blue circles). Median and interquartile ranges are shown. I) Kaplan-Meier curve of PFS in patients with < median level of CD117+ EpCAM+ CTCs at pretreatment vs. those with ≥median CD117+ EpCAM+ CTCs. CTCs: circulating tumor cells; PR: partial response; SD: stable disease; PFS: progression-free survival. See also Table S3, Fig. S3.